Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments (2012 - 2026)

Gyre Therapeutics (GYRE) has reported Change in Acquisitions & Divestments for 13 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 9.98% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $14.3 million (up 27.9% YoY), while the FY2025 annual figure was $15.4 million, changed N/A from the prior year.
• Change in Acquisitions & Divestments grew to $10.1 million in Q1 2026 per GYRE's latest filing, from $4.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $11.2 million in Q1 2025 and bottomed at $2.5 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $7.0 million across 3 years, with a median of $7.2 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments plunged 90.92% — and 2026, when it fell 9.98%.
• Gyre Therapeutics' Change in Acquisitions & Divestments stood at $2.5 million in 2022, then surged by 69.29% to $4.2 million in 2025, then jumped by 137.63% to $10.1 million in 2026.
• Business Quant data shows GYRE's Change in Acquisitions & Divestments at $10.1 million in Q1 2026, $4.2 million in Q4 2025, and $11.2 million in Q1 2025.